Figure 9. Development of New Cytomegalovirus Disease (at any site) in Patients with Cytomegalovirus Retinitis who Received Ganciclovir Implant plus Placebo, Ganciclovir Implant plus Oral Ganciclovir, or Intravenous Ganciclovir

Figure 9. Development of New Cytomegalovirus Disease (at any site) in Patients with Cytomegalovirus Retinitis who Received Ganciclovir Implant plus Placebo, Ganciclovir Implant plus Oral Ganciclovir, or Intravenous Ganciclovir

In this randomized trial, 373 patients with AIDS and unilateral cytomegalovirus retinitis received one of three regimens: ganciclovir implant plus placebo, ganciclovir implant plus oral ganciclovir (1.5 g tid), or  intravenous ganciclovir (5 mg/kg bid x 14-21 days, then 5 mg/kg qd).  Patients who did not receive systemic therapy with either oral ganciclovir or intravenous ganciclovir had the highest cumulative probability of developing new cytomegalovirus disease (defined as contralateral retinitis or biopsy proven extraocular disease).  Patients who received the intraocular implant had lower rates of progression of their retinitis than those who received intravenous ganciclovir (data not shown).

This figure is based on data from Martin DF, Kuppermann BD, Wolitz RA, Palestine AG, Li H, Robinson CA. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group.  N Engl J Med. 1999;340:1063-70.

[Close Window]

From: HIV Web Study <www.hivwebstudy.org>
© 2006-11 University of Washington